Results 151 to 160 of about 113,759 (264)

Nexus of Whey Proteins, Gut Dysbiosis, and Colonic Health

Food Science &Nutrition, Volume 14, Issue 2, February 2026.
Whey proteins possess antimicrobial and prebiotic properties that modulate gut microbiota by promoting beneficial bacteria like Bifidobacterium while suppressing pathogens. This modulation enhances short‐chain fatty acid production and strengthens intestinal barrier integrity, potentially alleviating dysbiosis‐related conditions such as colitis and ...
Tolulope Joshua Ashaolu, Chi‐Ching Lee, Ozgur Tarhan, Ali Rashidinejad, Seid Mahdi Jafari   +4 more
wiley   +1 more source

Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 3, March 2026.
Karissa Chow, Amanda Binkley, Jessica Meisner, Samantha Huo, Matthew Hinton   +4 more
wiley   +1 more source

Chronic Antibiotic Use, Gut Microbiota Dysbiosis, and Increased Risk of Colorectal Cancer: An Emerging Threat

Health Science Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background and Aims The gut microbiota plays a vital role in host health by regulating metabolic processes, immune function, and epithelial barrier functions. Chronic use of antibiotics can alter this environment and introduce gut dysbiosis, which is defined as an alteration of microbial communities characterized by a loss of beneficial ...
Md Mohiuddin
wiley   +1 more source

Association of Proton Pump Inhibitor and Potassium‐Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5‐Aminosalicylic Acid in Patients With Ulcerative Colitis

JGH Open, Volume 10, Issue 2, February 2026.
ABSTRACT Aims Proton pump inhibitors (PPIs) and potassium‐competitive acid blockers (PCABs) are widely used for acid‐related disorders. Recent studies have raised concerns that acid suppression may alter gut microbiota and drug pharmacokinetics, potentially influencing therapeutic outcomes in patients with inflammatory bowel disease.
Shinsuke Otagiri, Takahiro Ito, Keiji Yagisawa, Ayumu Sugitani, Atsuo Maemoto   +4 more
wiley   +1 more source

Exploratory Clinical Study to Evaluate the Efficacy and Safety of Sulfasalazine for Immune Checkpoint Inhibitor (ICI)‐Induced Colitis

JGH Open, Volume 10, Issue 2, February 2026.
ABSTRACT Background The first‐choice treatment for immune checkpoint inhibitor (ICI)‐induced colitis is steroids; however, side effects may occur and survival may be reduced. Sulfasalazine (SSZ) is primarily used for inflammatory bowel disease but studies on ICI‐induced colitis are scarce.
Mariko Kobayashi, Takeshi Yamada, Shunsuke Ueyama, Yoshiyuki Yamamoto, Akinori Sugaya, Yoshinori Hiroshima, Takashi Mamiya, Junji Hattori, Shintaro Akiyama, Bryan J. Mathis, Kiichiro Tsuchiya   +10 more
wiley   +1 more source

Fluoroquinolone Prophylaxis Reduces Intensive Care Unit Admission and Clostridioides difficile Rates in Acute Myeloid Leukemia Induction Chemotherapy

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Background Patients with acute myeloid leukemia (AML) undergoing induction chemotherapy are at high‐risk of bloodstream infections, including central line‐associated bloodstream infections (CLABSI) or mucosal barrier injury‐related infections (MBI‐LCBI).
Charles J. Weeks, Sujith Abbagoni, Faizan Boghani, Priyanka Menon, Matthew Gold, Chandini Kannan, Ozal Ismayilov, Mark Dalgetty, Anvay Shah, Lydia Delay, Heeju Lim, Mohammad Mian, Andrea Clarke, Locke Bryan, Jorge Cortes, Anand Jillella, Vamsi Kota   +16 more
wiley   +1 more source

Toxic megacolon: A rare presentation and novel treatment

JPGN Reports, Volume 7, Issue 1, Page 40-43, February 2026.
Abstract A 14‐year‐old male presented with toxic megacolon (TM). Stool culture and rectal biopsies ruled out Clostridium difficile infection and Hirschsprung disease, respectively. Anorectal manometry ruled out anal achalasia as rectoanal inhibitory reflex elicited a normal resting pressure.
Adrienne P. Davis, Jennifer M. Schuh, Janice Bitong, Amy J. Wagner   +3 more
wiley   +1 more source

Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Stem cells offer multifaceted therapeutic approaches for inflammatory diseases, each exhibiting distinct therapeutic properties. Hematopoietic stem cells, primarily through hematopoietic stem cell transplantation (HSCT), can effectively remodel the immune environment, showing particular promise in treating genetically linked cases.
Chen Wu, Zhi‐Ping Jin, Shu‐Qiang Weng, Ji‐Min Zhu, Ling Dong   +4 more
wiley   +1 more source

Gut Microbial Variations Associated With Proton Pump Inhibitor Use in the Boston Puerto Rican Health Study

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT Proton pump inhibitors (PPI), used to treat gastrointestinal disorders, are associated with alterations in the gut microbiome. However, this is understudied in Puerto Ricans who have unique lifestyle characteristics. Puerto Ricans, including participants of the Boston‐Puerto Rican Health Study (BPRHS), report high PPI use.
Deepika Dinesh, Xochitl C. Morgan, Hanseul Kim, Tammy M. Scott, Mahdi Garelnabi, Jong Soo Lee, Kelsey M. Mangano, Long H. Nguyen, Curtis Huttenhower, Katherine L. Tucker, Natalia Palacios   +10 more
wiley   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings, Serbülent Ünsal, Mathieu Rappas, Matthew Barnes, Maria Waldhoer, Ben Holland, Martin Culka   +6 more
wiley   +1 more source